EHA 2018 and Precision Medicine View overview page

1:12
Using biomarkers and genomics to inform treatment strategy in ALL
Thomas Alexander • 14 Jun 2018
1:34
Using MRD to guide MM treatment
Nikhil Munshi • 14 Jun 2018
1:54
Genome sequencing and transcription analysis: improving MM understanding
Nikhil Munshi • 14 Jun 2018
2:34
Early MRD negativity predicts depth of response to CAR T-cells in R/R MM
Nikhil Munshi • 14 Jun 2018
1:54
Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
Arnon Kater • 14 Jun 2018
3:27
Using MRD to inform CLL treatment in a clinical trial
Pierre Feugier • 14 Jun 2018
1:06
Response to MM therapy can vary based on a variety of factors
Shaji Kumar • 14 Jun 2018
3:02
New technologies informing SOC in DLBCL
Christian Gisselbrecht • 14 Jun 2018
2:06
Genetic profiling for high-risk MM is practical in a short timeframe
Matthew Jenner • 14 Jun 2018
2:57
MRD in AML: prognoses, transplant and treatment planning
Mohamad Mohty • 14 Jun 2018
2:40
UKALL14: implementing genetics in ALL research
Anthony Moorman • 14 Jun 2018
2:43
MURANO update: MRD, biological subsets & safety analysis
John Seymour • 14 Jun 2018
1:39
Using MRD to inform allocation of stem cell transplants in ALL and AML
Fabio Guolo • 14 Jun 2018
1:52
How should MRD be used for MM in routine clinical practice?
Bruno Paiva • 14 Jun 2018
2:23
Combining MRD with genetic knowledge in ALL
Anthony Moorman • 14 Jun 2018
2:28
Preventing early disease progression in follicular lymphoma
John Seymour • 14 Jun 2018

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals